Jacobi Capital Management’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.7M | Buy |
72,285
+257
| +0.4% | +$29.7K | 0.49% | 31 |
|
|
2025
Q4 | $7.58M | Buy |
72,028
+449
| +0.6% | +$42.1K | 0.44% | 37 |
|
|
2025
Q3 | $6.01M | Buy |
71,579
+2,288
| +3% | +$188K | 0.37% | 48 |
|
|
2025
Q2 | $5.49M | Buy |
69,291
+4,780
| +7% | +$380K | 0.36% | 51 |
|
|
2025
Q1 | $5.79M | Buy |
64,511
+2,722
| +4% | +$254K | 0.43% | 45 |
|
|
2024
Q4 | $6.15M | Buy |
61,789
+1,498
| +2% | +$154K | 0.46% | 37 |
|
|
2024
Q3 | $6.85M | Buy |
60,291
+1,763
| +3% | +$209K | 0.52% | 32 |
|
|
2024
Q2 | $7.25M | Buy |
58,528
+883
| +2% | +$114K | 0.63% | 23 |
|
|
2024
Q1 | $7.61M | Sell |
57,645
-4,202
| -7% | -$518K | 0.7% | 21 |
|
|
2023
Q4 | $6.74M | Buy |
61,847
+1,844
| +3% | +$191K | 0.69% | 24 |
|
|
2023
Q3 | $6.18M | Sell |
60,003
-50
| -0.1% | -$5.39K | 0.7% | 25 |
|
|
2023
Q2 | $6.93M | Buy |
60,053
+1,003
| +2% | +$114K | 0.78% | 20 |
|
|
2023
Q1 | $6.28M | Buy |
59,050
+1,134
| +2% | +$122K | 0.75% | 19 |
|
|
2022
Q4 | $6.43M | Buy |
57,916
+201
| +0.3% | +$20.5K | 0.8% | 20 |
|
|
2022
Q3 | $4.97M | Buy |
57,715
+891
| +2% | +$79.5K | 0.68% | 22 |
|
|
2022
Q2 | $5.18M | Sell |
56,824
-374
| -0.7% | -$33.2K | 0.69% | 24 |
|
|
2022
Q1 | $4.69M | Buy |
57,198
+319
| +0.6% | +$25.2K | 0.56% | 30 |
|
|
2021
Q4 | $4.36M | Buy |
56,879
+3,442
| +6% | +$274K | 0.52% | 31 |
|
|
2021
Q3 | $4.01M | Buy |
53,437
+2,698
| +5% | +$205K | 0.51% | 28 |
|
|
2021
Q2 | $3.95M | Buy |
50,739
+2,917
| +6% | +$217K | 0.52% | 29 |
|
|
2021
Q1 | $3.52M | Buy |
47,822
+6,580
| +16% | +$485K | 0.52% | 27 |
|
|
2020
Q4 | $3.19M | Sell |
41,242
-5,213
| -11% | -$399K | 0.5% | 30 |
|
|
2020
Q3 | $3.62M | Buy |
46,455
+168
| +0.4% | +$13.2K | 0.64% | 27 |
|
|
2020
Q2 | $3.44M | Buy |
46,287
+2,483
| +6% | +$187K | 0.64% | 28 |
|
|
2020
Q1 | $3.27M | Buy |
43,804
+4,155
| +10% | +$327K | 0.7% | 26 |
|
|
2019
Q4 | $3.35M | Buy |
39,649
+160
| +0.4% | +$13.1K | 0.61% | 28 |
|
|
2019
Q3 | $3.14M | Sell |
39,489
-931
| -2% | -$74.6K | 0.62% | 28 |
|
|
2019
Q2 | $3.24M | Buy |
40,420
+23,563
| +140% | +$1.8M | 0.66% | 26 |
|
|
2019
Q1 | $1.34M | Sell |
16,857
-667
| -4% | -$49.9K | 0.34% | 48 |
|
|
2018
Q4 | $1.28M | Buy |
17,524
+2,923
| +20% | +$206K | 0.35% | 45 |
|
|
2018
Q3 | $988K | Buy |
14,601
+497
| +4% | +$31.7K | 0.26% | 57 |
|
|
2018
Q2 | $817K | Buy |
14,104
+2,180
| +18% | +$123K | 0.24% | 62 |
|
|
2018
Q1 | $606K | Buy |
11,924
+3,692
| +45% | +$199K | 0.18% | 73 |
|
|
2017
Q4 | $445K | Buy |
8,232
+1,769
| +27% | +$98.1K | 0.14% | 90 |
|
|
2017
Q3 | $397K | Buy |
6,463
+2,127
| +49% | +$129K | 0.13% | 89 |
|
|
2017
Q2 | $260K | Sell |
4,336
-106
| -2% | -$6.45K | 0.1% | 101 |
|
|
2017
Q1 | $269K | Buy |
4,442
+757
| +21% | +$45.9K | 0.14% | 75 |
|
|
2016
Q4 | $217K | Sell |
3,685
-906
| -20% | -$53K | 0.13% | 75 |
|
|
2016
Q3 | $274K | Buy |
4,591
+1
| +0% | +$58 | 0.13% | 71 |
|
|
2016
Q2 | $259K | Buy |
+4,590
| New | +$244K | 0.13% | 71 |
|
Other funds holding MRK
VCM
VPM
Jacobi Capital Management's MRK Position: Q1 2026 in Review
Jacobi Capital Management increased its Merck (MRK) stake by 0.36% in Q1 2026, buying an estimated $29.7K and bringing the position to 72,285 shares worth $8.7M. The position accounts for 0.49% of the portfolio, ranked #31.
Jacobi Capital Management first reported a position in MRK in Q2 2016 and has held it in 40 quarters since. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Jacobi Capital Management held 72,285 shares of Merck worth $8.7M as of Q1 2026.
- Jacobi Capital Management bought 257 Merck shares in Q1 2026, an estimated $29.7K.
- Merck made up 0.49% of Jacobi Capital Management's portfolio in Q1 2026, its #31 holding.
- Jacobi Capital Management first reported a position in Merck in Q2 2016 and has held it in 40 quarters since.
- 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Jacobi Capital Management's 13F filing for Q1 2026, filed 14 May 2026.